Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

A mathematical model suggests that existing HPA-targeting drugs failed in clinical trials for mood disorders because the ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

More than 5 million Americans struggle with opioid use disorder, a physical addiction entwined with America’s health crisis, ...

Repurposing drugs could "save millions of pounds and decades it takes to develop a new dementia drug from scratch" ...

The newly FDA-approved nasal spray called Spravato is being manufactured by Johnson & Johnson's and is a standalone treatment ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

A systematic review of existing medicines has found that antibiotics and vaccinations are associated with a reduced risk of ...